My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$HBAN {{ '2016-01-21T14:59:24+0000' | timeago}} • Webcast

$HBAN said that it expects NIM pressure will remain a headwind in the near term & will bottom out later this year assuming no interest rate increase and will remain above 3%.

User Leroy John {{ '2016-10-28T19:51:40+0000' | timeago}}

Vine, the unique app from $TWTR is no more! Perfect example for mass products that don't make money!

User Melwyn Jones {{ '2016-10-28T17:16:30+0000' | timeago}}

$CVX posts first profit in a year. Right time to get some shares? My question is, will it sustain this turnaround?

User Josh Allan {{ '2016-10-27T15:39:01+0000' | timeago}}

Jeff Bezos, my inspiration next to Steve Jobs is going to review the Everything Store $AMZN's financial results today after hours. As an investor/user, I like Amazon Prime and it's success over several parts of the world. What's your take on Amazon?

User RC xNair {{ '2016-10-27T13:31:32+0000' | timeago}}

Of all the Wall St firms out there, Goldman Sachs $GS is the most revered for the way they're run - hiring the best, highly competitive, a closely-knit peer group and making tons of profits for the shareholders. An interesting interview of its CEO Llyod Blankfein by Carlyle groups chief David Rubenstein

User Ramesh Raju {{ '2016-10-27T10:38:07+0000' | timeago}}

Deutsche Bank posts Q3 net profit of 278 million euros.

$FLS {{ '2016-10-28T20:53:40+0000' | timeago}} • Webcast

$FLS said FY16 capital expenditures are expected to be in the range of $105-115MM, a significant reduction over elevated FY15 levels. Cash realignment expenditures are expected to be in the range of about 125-150MM.

$FLS {{ '2016-10-28T20:43:11+0000' | timeago}} • Webcast

$FLS expects FY16 adjusted EPS in the range of $2.05-2.25 per share. Revenue is expected to decline 11-14%, including 2% currency headwind. Realized cost savings is expected to be about $100MM.

$AFL {{ '2016-10-28T20:20:01+0000' | timeago}} • Webcast

$AFL said the revision to EPS guidance was largely bolstered by outperformance on earnings in the US. YTD, both the US and Japan regions have been trending favorably in terms of benefit ratios and expense ratios. Solid results from Japan have also contributed to the revision.

$HSY {{ '2016-10-28T20:06:44+0000' | timeago}} • Webcast

$HSY's North America segment income was $563.9MM, up 3.3% from a year ago. The increase was helped by an increase in gross profit of about 1%, and lower advertising and related consumer marketing expense.

$ABMD {{ '2016-10-28T20:03:23+0000' | timeago}} • Announcement

$ABMD received the U.S. Food and Drug Administration (FDA) approval of a prospective feasibility study. The study will evaluate use of Impella CP heart pump for unloading of left ventricle prior to primary percutaneous coronary intervention in patients presenting with ST segment elevation myocardial infarction, without cardiogenic shock.